A-05 Novel Therapeutic Strategy for B Cell Malignant Lymphocyte
ΓùÅ CD20 negatively converted B cell malignant lymphocyte cell line is availableΓùÅ An animal model indicating the pathological conditions of CD20-negatively converted B cell malignant lymphocyte is availableΓùÅ A method is available for screening a substance which is efficacious against CD20 positive B cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte.
ΓùÅ Treatment for rituximab resistant B cell malignant lymphocyteΓùÅ Screening agent for rituximab resistant B cell malignant lymphocyte
A) RRBL1 is CD20 negative, resistant to rituximab B cell malignant lymphocyte. Isolated rituximab resistant B cell malignant lymphocyte. This cell line shows rituximab resistance in vitro and feasible to be transplanted into an immunodeficient mouse.B) Induction of CD20 expression by RRBL1 treatment. CD20-negative conversion phenomena after treatment with rituximab is detected in ┬╝ of recurrence. Treating this cell line by various drugs, an effective condition was verified which would induce CD20 expression. This condition will induce protein expression of CD20 on the cell surface.
Patent Number: HK1054628A1
Application Number: HK2003106837A
Inventor: LIU CHIU-PONG JOE | POON NGAI-KIT FRANKI | PONG MAN-HAY BRYAN
Priority Date: 24 Aug 2001
Priority Number: HK1054628A1
Application Date: 23 Sep 2003
Publication Date: 23 Dec 2005
IPC Current: B29C004576 | G06F000130 | H02M000112
Assignee Applicant: The University of Hong Kong
Title: Apparatus for noise current reduction in power converters.
Usefulness: Apparatus for noise current reduction in power converters.
Disease Diagnostic/Treatment
Other Disease
USA
